Date: 2013-01-22
Type of information: Fundraising
Company: Lophius Biosciences (Germany)
Investors: VRD GmbH (Germany) WIC GmbH (Germany) S-Refit (Germany) HighTech Gründerfonds (HTGF) (Germany) Bayern Kapital (Germany) two Business Angels
Amount: € 4 million
Funding type:
Planned used: With these funds, Lophius Biosciences intends to fully introduce its technologies and products in the field of T-cell based diagnostics.
Others: * On January 22, 2013, Lophius Biosciences, a developer of novel, innovative T-cell-based diagnostic test systems, announced the closing of a further financing round. With VRD GmbH and WIC GmbH two new investors will financially support the company alongside existing investors such as S-Refit, HighTech Gründerfonds (HTGF), Bayern Kapital and two Business Angels.
Prof. Dr. Ralf Wagner, former CEO of GeneArt AG, has been appointed as Managing Director in order to drive the further development of the company together with the current Managing Director Dr. Michael Lutz.
Prof. Wagner was founder, CEO and CSO of Regensburg-based company GeneArt AG which specialized in the field of synthetic biology. Following the acquisition by Life Technologies in 2010 he was responsible as Site leader and Vice President Synthetic Biology for the successful integration of GeneArt AG into Life Technologies. As professor for molecular microbiology and gene therapy, Dr Wagner is also member of the Medical faculty at the University of Regensburg.
Therapeutic area: Diagnostic
